Advanced Breast Cancer
Standard of care testing for BRCA1/2, ERBB2 (HER2), MSI, ESR1, NTRK1/2/3, and PIK3CA.
Download Study
Pre-treatment imaging
Post-treatment imaging
*Representative patient images
Patient Case
Clinical presentation
- 56-year-old female previously treated for early-stage breast cancer
- Patient was ER+/HER2-
- Upon metastatic progression, she was put on CDK4/6 inhibitor (IBRANCE®)
- After 10 months of therapy, the patient showed signs of clinical progression via CT scan
Testing
- Patient had no prior genomic testing
- Oncologist ordered Guardant360® to receive guideline-recommended results within 7 days-
- The patient was found to have an activating PIK3CA mutation
Treatment
- Oncologist started the patient on a PI3K inhibitor with a partial response that lasted more than 9 months
